Novocure Ltd (NVCR NASDAQ) stock market data APIs
$17.3151
-1.55(-9%)
as of July 2, 2026
Try our APIs with
free plan!
Novocure Ltd Financial Data Overview
Price chart is built with
Anychart
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Prev. Close
17.3151
Open
15.7651
High
17.3425
Low
15.5278
52 wk Range
9.82-18.92
Market Cap
1 992 M
Shares Outstanding
116 M
Revenue
674 M
EPS
-0.62
Beta
0.935
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Novocure Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novocure Ltd data using free add-ons & libraries
Get Novocure Ltd Fundamental Data
Novocure Ltd Fundamental data includes:
- Net Revenue: 674 M
- EBITDA: -166 215 008
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-30
- EPS/Forecast: -0.51
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novocure Ltd News
New
NovoCure's Cancer Treatment Device Option Pax Gets European Approval
NovoCure Limited NVCR recently announced that its portable medical device, Option Pax, has received the CE (Conformité Européenne) mark for treating adult patients with locally advanced pancreatic c...
Novocure to Report Second Quarter 2026 Financial Results
BAAR, Switzerland, July 01, 2026--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are ...
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with...
Get Novocure Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
